Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile By Ogkologos - October 6, 2026 51 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PATHFINDER 2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Clinical Trials in Genitourinary Cancers: TALAPRO-2, KEYNOTE-905, and COSMIC-313 July 9, 2020 FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma April 27, 2022 Researchers May Be Able to Predict Breast Cancer Metastasis by Changes... December 3, 2021 High-Deductible Health Plans Linked to Delayed Diagnosis and Treatment of Breast... April 23, 2019 Load more HOT NEWS Real-World Patients with Cancer Show Lower Survival Times and Treatment-Associated Survival... ΚΑΡΚΙΝΟΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ Researchers Discover Way to Help Immunotherapy Better Target Solid Tumors Like... 2025 ESMO Society Award recipients announced
